IN2015MU03858A - - Google Patents
Info
- Publication number
- IN2015MU03858A IN2015MU03858A IN3858MU2015A IN2015MU03858A IN 2015MU03858 A IN2015MU03858 A IN 2015MU03858A IN 3858MU2015 A IN3858MU2015 A IN 3858MU2015A IN 2015MU03858 A IN2015MU03858 A IN 2015MU03858A
- Authority
- IN
- India
- Prior art keywords
- micafungin
- sodium
- formulation
- micafungin sodium
- disaccharide
- Prior art date
Links
- 108010021062 Micafungin Proteins 0.000 abstract 3
- KOOAFHGJVIVFMZ-WZPXRXMFSA-M micafungin sodium Chemical compound [Na+].C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS([O-])(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 KOOAFHGJVIVFMZ-WZPXRXMFSA-M 0.000 abstract 3
- 229960004806 micafungin sodium Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229960002159 micafungin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3858MU2015 IN2015MU03858A (enExample) | 2015-10-10 | 2016-10-07 | |
| PCT/IN2016/050341 WO2017060923A1 (en) | 2015-10-10 | 2016-10-07 | Freeze dried parenteral formulation of micafungin sodium and to process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3858MU2015 IN2015MU03858A (enExample) | 2015-10-10 | 2016-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MU03858A true IN2015MU03858A (enExample) | 2015-10-23 |
Family
ID=54398093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3858MU2015 IN2015MU03858A (enExample) | 2015-10-10 | 2016-10-07 |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2015MU03858A (enExample) |
| WO (1) | WO2017060923A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017376960B2 (en) * | 2016-12-16 | 2023-12-14 | Baxter Healthcare Sa | Micafungin compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2525831B1 (en) * | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
| CN102614491B (zh) * | 2011-01-31 | 2014-04-16 | 上海天伟生物制药有限公司 | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 |
| CN103330933B (zh) * | 2013-04-26 | 2015-08-05 | 江苏豪森药业股份有限公司 | 含有米卡芬净或其盐的药物组合物 |
-
2016
- 2016-10-07 IN IN3858MU2015 patent/IN2015MU03858A/en unknown
- 2016-10-07 WO PCT/IN2016/050341 patent/WO2017060923A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017060923A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500720A1 (en) | Glycopeptide compositions | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| AU2018256640A1 (en) | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | |
| AU2015336400A8 (en) | Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof | |
| MX2018002627A (es) | Metodo de cristalizacion y biodisponibilidad. | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| PH12017502376B1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| MX2020007552A (es) | Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| NZ728401A (en) | High purity oritavancin and method of producing same | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| GEP20237486B (en) | Formulations of copanlisib | |
| CA3011436C (en) | VANCOMYCIN-BASED FORMULATIONS | |
| IN2015MU03858A (enExample) | ||
| PH12018501758A1 (en) | Oritavancin formulations | |
| GR1008234B (el) | Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| IL253370A0 (en) | Preparations containing hydroxy-cinnamic acid, conjugates, analogues, derivatives and methods of using them | |
| MX2019008847A (es) | Profarmacos de cisteamina. | |
| MX2017010992A (es) | Composiciones farmaceuticas estables que comprenden agente antibacteriano. | |
| WO2016079749A3 (en) | Process for preparation of parenteral formulation of anidulafungin | |
| UA91650U (uk) | Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул | |
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof |